International outcomes in breast, cervical, and ovarian cancers highlight opportunities to improve health-care delivery for ...

October 22, 2025. More for You ...

MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...

The potential benefits of GLP-1 medications continue to expand. New research has found that the weight loss and diabetes drugs — officially known as glucagon-like peptide 1 receptor agonists — are ...

Sponsored by GSK. Sherry is a patient with endometrial cancer who will be discussing her experience; individual experiences may vary. Sherry has been compensated by GSK for her participation in this ...

Imlunestrant approval targets ER-positive, HER2-negative, ESR1-mutated advanced breast cancer post-endocrine therapy progression. EMBER-3 trial showed imlunestrant reduced disease progression or death ...

ALBUQUERQUE, N.M. — A professor at the University of New Mexico Comprehensive Cancer Center has been awarded a 5-year, $12.9 million grant to study endometrial cancer. Dr. Kimberly Leslie is set to ...

It was quite a red flag. Alla Feldbeyn was stunned by unexpected vaginal bleeding in November 2020, many years after she had gone through menopause. The Florida grandmother of four was diagnosed with ...

Side effects depend on treatment type, and it’s important to tell your healthcare provider if you notice any. “Patients should be familiar with what signs and symptoms to monitor ‌and feel encouraged ...

While anticancer treatments, including many forms of chemotherapy and radiation, can effectively kill cancer cells, long-term use can cause mutations in healthy cells. Mutations arising in cells that ...

Genmab has received breakthrough therapy designation from the U.S. Food and Drug Administration for its endometrial cancer treatment. The biotechnology company said Tuesday the decision was supported ...

Rina-S has received FDA breakthrough therapy designation for advanced endometrial cancer after standard treatments fail, based on promising Phase 1/2 trial results. The RAINFOL-01 trial showed ...